Zip, ah, okay...makes sense but I still think the SPA reinstatement and (conditional) approval of Anchor makes Vascepa an attractive acquisition target for BP which will help drive up the price. In the husband and wife scenario, it's the wife who invested (me) and has to explain to husband that I am not crazy, that it really will pay off in the end. :)
Market Data 
Markets 
AI
